What is an antibody‑drug conjugate (ADC) medication?

What is an Antibody-Drug Conjugate (ADC) Medication?

An antibody-drug conjugate (ADC) is a targeted cancer therapy that combines a monoclonal antibody with a potent cytotoxic drug, connected by a chemical linker, designed to deliver chemotherapy directly to cancer cells while minimizing damage to healthy tissue. 1, 2, 3

Core Structure and Components

ADCs consist of three essential components that work together to achieve targeted cancer cell killing:

• Monoclonal antibody: Targets specific antigens expressed on tumor cell surfaces (e.g., HER2, BCMA, Trop-2, CD22, CD37, Nectin-4)
• Cytotoxic payload: A highly potent chemotherapy agent that kills cancer cells (common payloads include topoisomerase I inhibitors like DXd, microtubule inhibitors like DM1 or MMAF, or alkylating agents)
• Chemical linker: Connects the antibody to the payload and controls when and where the drug is released (can be cleavable or non-cleavable) 4, 1, 3, 5

Mechanism of Action

The primary mechanism of ADC activity relies on targeted delivery of cytotoxic molecules rather than blockade of signaling pathways. This is particularly important in HER2-low breast cancer, where traditional anti-HER2 antibodies (like trastuzumab alone) failed to show benefit, but ADCs like trastuzumab deruxtecan demonstrated remarkable efficacy 2.

The ADC works through this sequence:

1. The antibody binds to target antigens on cancer cell surfaces
2. The entire ADC-antigen complex is internalized into the cell
3. The linker is cleaved (if cleavable) or degraded in lysosomes
4. The cytotoxic payload is released inside the cancer cell
5. The payload kills the cancer cell through its specific mechanism (e.g., DNA damage, microtubule disruption)
6. Some ADCs exhibit a "bystander effect" where released payload can kill neighboring tumor cells that lack the target antigen 1, 2, 6

Currently Approved ADCs

As of 2025, 15 ADCs have received FDA approval, with the most clinically significant including:

In Breast Cancer:

• Trastuzumab deruxtecan (T-DXd): HER2-targeting ADC with topoisomerase I inhibitor payload, approved for HER2-positive and HER2-low metastatic breast cancer 1, 7
• Trastuzumab emtansine (T-DM1): HER2-targeting ADC with microtubule inhibitor (DM1) payload 4, 1
• Sacituzumab govitecan: Trop-2-targeting ADC with topoisomerase I inhibitor (SN-38) payload, approved for triple-negative breast cancer after ≥2 prior therapies 8

In Multiple Myeloma:

• Belantamab mafodotin: BCMA-targeting ADC with MMAF payload for relapsed/refractory multiple myeloma 3, 9

Other Malignancies:

Multiple ADCs targeting CD22, CD37, CD79b, and Nectin-4 are approved or in development for lymphomas, leukemias, and bladder cancer 10, 7

Clinical Advantages Over Traditional Chemotherapy

ADCs overcome fundamental limitations of conventional chemotherapy by:

• Improving therapeutic index: Delivering higher concentrations of cytotoxic drugs to tumor cells while reducing systemic exposure
• Overcoming multidrug resistance: Many ADC payloads are not substrates for ABC transporters that cause chemotherapy resistance
• Enabling treatment of low-expressing targets: Second-generation ADCs can effectively target even low levels of antigen expression (e.g., HER2-low disease)
• Providing better tolerability: Generally fewer severe toxicities compared to traditional chemotherapy, though ADC-specific toxicities exist 2, 11

Important Toxicity Considerations

ADCs have unique toxicity profiles distinct from both traditional chemotherapy and naked antibodies:

Common ADC-Specific Toxicities:

• Ocular toxicity: Particularly with belantamab mafodotin, causing corneal microcyst-like changes, dry eye, and vision changes (reversible in almost all cases with dose modifications) 9
• Interstitial lung disease/pneumonitis: Notable with trastuzumab deruxtecan (13.6% incidence, fatal in 2.2%), requiring active surveillance and rapid intervention 7
• Hematologic toxicity: Neutropenia, thrombocytopenia (often more severe than with naked antibodies)
• Gastrointestinal toxicity: Diarrhea, nausea (payload-dependent)
• Peripheral neuropathy: With microtubule-inhibitor payloads 4, 1, 7

Critical safety point: Healthcare providers must be educated on recognizing and managing ADC-specific toxicities, as these differ substantially from traditional chemotherapy side effects.

Expanding Beyond Oncology

While currently approved ADCs are exclusively for cancer treatment, the ADC platform is being investigated for autoimmune diseases, persistent bacterial infections, and neurodegenerative diseases, representing a paradigm shift in targeted drug delivery 5, 12.

Key Clinical Pearls

• ADCs are not simply "chemotherapy plus antibody"—they represent a distinct therapeutic class with unique pharmacology
• Target antigen expression level matters, but even low expression (HER2-low) can be therapeutically relevant with potent ADCs
• Dose modifications for toxicity do not compromise efficacy—this is well-established for belantamab mafodotin ocular events 9
• The bystander effect allows some ADCs to kill antigen-negative tumor cells in heterogeneous tumors, a major advantage over traditional targeted therapies 2
• Resistance mechanisms to ADCs differ from traditional chemotherapy and include reduced antigen expression, impaired internalization, and altered lysosomal function 13, 11